



Date: May 4, 2020
To: All Zones
From: Genetics & Genomics, Alberta Precision Laboratories (APL)
Re: Karyotyping criteria for chorionic villi sampling (CVS) specimens

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

- **Effective May 4, 2020**, the chorionic villus sampling (CVS) criteria for karyotype has changed.
- CVS specimens will be eligible for karyotype **ONLY** when the fetus is at risk for an unbalanced chromosomal rearrangement and/or aneuploidy.
- This process change aligns the testing algorithms for CVS and amniocentesis specimens across the province.

Why this is important:

- Previously, karyotyping was performed inconsistently across prenatal specimens if the indication was for a single gene disorder.
- Now, karyotyping will **NOT** be performed on CVS specimens collected for single gene testing.
- There is no change to the indications or testing algorithms for RAD or chromosomal microarray testing. Testing for single gene disorders continues to be available on CVS and amniocentesis specimens.

Action Required:

- Refer to the APL Test Directory for requisition, collection and handling information at: <http://www.albertahealthservices.ca/3217.asp>

Inquiries and feedback may be directed to:

- Laboratory Genetic Counsellors, North 780-407-1015
- Laboratory Genetic Counsellors, South 403-955-3097

This bulletin has been reviewed and approved by:

Dr. Dennis Bulman, Medical/Scientific Director, Genetics & Genomics, APL
Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), APL